A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

Inclusion Criteria: * Aged at least 18 years at the time of consent. * Confirmed diagnosis of metastatic pancreatic adenocarcinoma (PDAC) within the 6 weeks prior to study start and have not received treatment for metastatic PDAC. * Have measurable disease by RECIST v1.1. * Eligible for treatment with mFOLFIRINOX as standard of care therapy. * Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1 * Have a life expectancy of \> 3 months. * Adequate organ function * Agree to use effective contraception. Exclusion Criteria: * Pregnant or breast-feeding * Have received any investigational medicinal product (IMP) within 30 days or 5 half-lives (whichever is longer) prior to Day -7. * Neuroendocrine or acinar cell pancreas tumors. * Known brain metastases. * Conditions that could interfere with the swallowing or absorption of study medication. * Received previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease. * Received cytotoxic doses of any 5-FU based chemotherapy. * Any chemotherapy related toxicities greater than grade 1 from prior neoadjuvant or adjuvant therapy for PDAC. * Human immunodeficiency virus (HIV) infection and/or history of Hepatitis B infection or known to have active hepatitis B or C. * Uncontrolled angina, myocardial infarction, coronary stenting, stroke, or cerebrovascular accident within 1-year prior to the first dose of study drug. * History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis. * Clinical signs of active infection at the time of Screening or Baseline. * Clinically significant allergies to narmafotinib, mFOLFIRINOX components (or any of their excipients) that are not likely to be well controlled with pre-medication or other supportive measures. * Any of the conditions or events outlined in the Contraindications or Special Warnings and Precautions sections of the mFOLFIRINOX component package inserts. * Peripheral neuropathy \> Grade 1. * Prior treatment with narmafotinib or other FAK inhibitor within the 2 years prior to screening.